[Experience with high-dose methotrexate therapy for malignant solid tumors].
Thirteen patients with malignant solid tumors, mainly osteogenic sarcomas, were treated by high-dose MTX therapy, 50-400 mg/kg, in a total of 72 cycles. It has been proved that this therapy was relatively safe provided careful clinical surveillance were assured. Of 8 patients with osteogenic sarcomas, 6 had no metastatic lesions on the chest X-rays before this therapy: three were alive without any evidence of disease for 18-25 months after high-dose MTX therapy. In some cases of other malignant solid tumors, particularly intracranial tumors, clinical efficacy was observed. Dose-time relationships, etc. should further be studied for more therapeutic efficacies of high-dose MTX therapy.
D000293:Adolescent; D000328:Adult; D001932:Brain Neoplasms / Q000188:drug therapy; D002648:Child; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005910:Glioma / Q000188:drug therapy; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D009362:Neoplasm Metastasis; D012516:Osteosarcoma / Q000188:drug therapy*; D011149:Pons
D008727:Methotrexate